Boston, MA – According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $51,772,544.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Caroline Godfrey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PepGen
PepGen’s ambition is to harness the power of peptide conjugation technologies in order to address the delivery challenge associated with nucleic acid therapeutics and thus realise the clinical potential of these transformative therapeutics. There is a deep need for a paradigm shift in genomic medicine, and PepGen’s innovative peptides are ideally positioned to effect this change for patients, families and the broader healthcare community.

To learn more about PepGen, visit http://pepgen.com/

Contact:
Caroline Godfrey, President and Chief Executive Officer
703-456-8000
https://www.linkedin.com/in/caroline-godfrey-8b289a21/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved